chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Chills; Fever; Night Sweats; Headache; Muscle Aches; Exhaustion; This is a spontaneous report from a non contactable consumer, the patient. A 45-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; lot number: EN6207) via an unspecified route of administration in the left arm on 18March2021 at 14:30 (at the age of 45-year-old), as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. The patient was allergic to penicillin. The patient had not received any other vaccines within four weeks prior to the vaccination. It was unknown whether prior to vaccination, patient was diagnosed with COVID-19. Since the vaccination, the patient had not tested for COVID-19. On 19March2021 at 15:00, the patient experienced chills, fever, night sweats, headache, muscle aches and exhaustion. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the adverse events. The clinical outcome of the events chills, fever, night sweats, headache, muscle aches, exhaustion was recovered on an unknown date in Mar2021.   No follow-up attempts are needed. No further information is expected.
Client complained of swelling and tenderness of armpit in arm vaccine was given on Saturday morning, Mother stated had given ibuprophen over the weekend. Mother reports client still having tenderness and swelling in armpit today.
Right arm became red, swollen, warm on 11/28/2006. Area of erythema at office visit = 3 inches circular with mild swelling (date of visit 1/30/2006). Full ROM, no fevers. According to mom, much improved with topical hydrocortisone cream over last 24 hours.
Within 15 minutes of administration Meningococcal vaccine patient exhibited scant generalized petechiae less than 1 mm in diameter on left arm between wrist and deltoid muscle. No respiratory distress or evidence of petechiae on abdomen, or other extremities.  No other untoward signs noted.  Home with Mother, if develops any other symptoms to take to PP or ED. @ 3:00 pm phone call to Mother, "no change in petechiae, no other problems @ this time.  Will follow-up 3/23/10.
Site: Pain at Injection Site-Severe, Site: Swelling at Injection Site-Severe, Additional Details: patient started experience a sore arm day after the injection. Says this has progressivly got worse each day and there is a nodule at the injection site. States that she is not able to use her arm for normal activity due to pain.
on an unspecified date pt was vax w/1st dose of varicella & subsequently the pt devel local erythema & duration at inject site pt notes to be ``very sensitive person''
On 02/03/2021 @ 1 am (approx. 1 wk. after 1st vaccine shot), started having pains under ribcage. Pains off and on until on 02/09/2021 about 3 am when the pain got so bad I went to the emergency room.  Diagnosed with pulmonary embolism.  Never had a blood clot or DVT before.  Blood test found I had Factor V. Had pain again under ribcage one week after second vaccine, but blood thinners appears to have dissolved if it was a clot.  My father then tested and found positive for Factor V after my diagnosis.  He then had a blood clot in leg approx 3 weeks after his second Pfizer vaccine, and had never had a blood clot like that before.   Appears to be a connection between Factor V and blood clots after Covid vaccines.
Egg size swelling, redness, and very painful shoulder, pain not relieved by Ibuprofen and Tylenol-ongoing. Redness and swelling have deminished. Extreme fatigue, ongoing nausea, aches, and malaise. All ongoing today.
pt recv vax & exp a mild rash;pt devel a severe case of tonsillitis;
Fever, aches, chills - first 2 days. Took TYLENOL. Rash, thick tongue, difficulty breathing - 5 days out told to go to hospital, take BENADRYL - have not been able to contact.
fatigue; nausea; This is a spontaneous report from a contactable nurse(patient herself). A 29-year-old female patient received the first dose of BNT162B2(PFIZER-BIONTECH COVID-19 VACCINE solution for injection; batch/lot number and expiry date were unknown) via an unspecified route of administration in the right arm on 20Jan2021 11:00 (at the age of 29-years-old) at a single dose for covid-19 immunization in a pharmacy or drug store. Medical history included Hashimoto's disease, anxiety and depression; all of which started from an unknown date and unknown if ongoing. Concomitant medications included piroxicam (PAXIL) and bupropion hydrochloride (WELLBUTRIN), both taken for an unspecified indication and start and stop dates were not reported. The patient was not pregnant at the time of vaccination. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has not been tested for COVID-19. The patient has no allergies to medications, food, or other products. On 24Jan2021 23:00, the patient experienced fatigue and nausea and reported that she has been experiencing the events since her shot. Events resulted in physician office visit. The events were reported as non-serious. It was unknown if a treatment was received for the events. The outcome of these events was not recovered.  Information on the lot/batch number has been requested.
Within 15 minutes of vaccine administration mother noted swelling at site of administration in left leg. Pt had approximately 4cm area of edema and erythema. Swelling decreased with ice. Mother told to return if sx persist. Could not reach her by phone to confirm complete resolution. Pt well and afebrile after vaccination.
Patient arrived at Clinic for second dose of Moderna.  Patient was checked in by CCMA.    Patiient was assigend to a Pfizer bay.   RN administered Pfizer vaccine to patient.  Patient had provided vaccination card and Pfizer label placed on it.  Upon check out it was noticed that patient had received Pfizer as oppossed to receiving his second dose  of Moderna.   DNP Supervisor was notiifed by RN charge for 2/14. I communicated with patient that there was no need to receive an additional dose of Moderna  : that it was not ideal that he received the 2 different vaccines but that it shouldn't be harmful;   that the vaccines are similar and that he should receive optimal immunity effacacy.
Received the vaccine on 1/5/2021 On 1/6/2021Approximately 24 hours after vaccine patient noted sore throat, lost voice, voice raspy took Benadryl with relief of symptoms the following day 1/7/2021 (could not take Benadryl due to working and concern over being  tired), symptom returned On the evening of 1/7/2021, symptom completely resolved pt concerned over if this was  angioedema  ,
Woke up with severe chest pains, pale , blue lips, nausea, clammy. Brought him to  Medical Center emergency room. Bloodwork, chest xray and EKG done. Bloodwork showed high lveles of troponin. Transported via ambulance to a d Medical Center pediatric intensive care unit. During stay at hospiatl he had telemetry monitoring, ekg, and regular bloodwork to check troponin levels. Diagnosed with Myopericarditis
h e had headaches and started throwing up. He had fever for 24 hours. His fever was around 101.5 for 12 hours.
Palpitation, body aches, shortness of breath, severe headache on the administration date (10/20/16) -> she went to ER and was treated on 10/22-10/23.
HEADACHE; CHILLS; MYALGIA; This spontaneous report received from a patient concerned a female of unspecified age. The patient's weight, height, and medical history were not reported.The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, intramuscular, batch number: 1802068, and batch number: 1802068 expiry: UNKNOWN) .5 ml, administered on MAR-2021 for prophylactic vaccination. No concomitant medications were reported. On 07-MAR-2021, the subject experienced chills. On 07-MAR-2021, the subject experienced myalgia. On 08-MAR-2021, the subject experienced headache. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from chills, and myalgia on 08-MAR-2021, and had not recovered from headache. This report was non-serious.
Patient stated she felt dizzy after vaccination. Let patient sit down for more than 15 minutes after vaccination and provided water. Said that she felt okay to return to work and that she only had couple hours left of shift. Towards end of shift said she still felt dizzy and called and reported adverse event.
Pt reported urticaria starting PM after injection on 1/22/02 in AM. Started on Prednisone and Claritin on 1/30/02. Pt still having problems on and off as of today.
Tingling, then tightness in throat.  Lungs clear. Evaluated by EMS on site then sent to ED.
Large rash  (fist sized) appeared on arm at injection site 8 days post-injection, very itchy
This spontaneous report as received from a nurse refers to a 65 year old female patient. On 09-OCT-2014 the patient was vaccinated with PNEUMOVAX 23, lot # K004148, expiry date 10-MAY-2015, 0.5 ml, intramuscular. On 09-OCT-2014, the patient experienced pain at the injection site, pain and weakness radiated to the shoulder and into the upper back. Nurse reported that when patient was seen on 14-OCT-2014, pain had resolved on an unknown date in October 2014, but weakness continued. No treatment was given for the events. The patient had sought medical attention by calling nurse. This is one of several reports from the same reporter. Additional information has been requested.
could not get out of bed; dizziness; weakness; nauseous; This spontaneous case was reported by a consumer and describes the occurrence of SOMNOLENCE (could not get out of bed), DIZZINESS (dizziness), ASTHENIA (weakness) and NAUSEA (nauseous) in a 78-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 013L20A) for COVID-19 vaccination.     Concurrent medical conditions included Hypertension, Diabetes and Diabetic eye disease. Concomitant products included CLONAZEPAM (KLONOPIN), ACETYLSALICYLIC ACID (ASPIRIN 81), CLOPIDOGREL BISULFATE (PLAVIX), DILTIAZEM HYDROCHLORIDE (CARDIZEM CD), EZETIMIBE (ZETIA), GLIPIZIDE (GLIPIZIDE XL), METFORMIN, LOSARTAN, OMEPRAZOLE (PRILOSEC [OMEPRAZOLE]), OXYBUTYNIN HYDROCHLORIDE (OXYBUTIN) and PRAVASTATIN for an unknown indication.    On 25-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced SOMNOLENCE (could not get out of bed), DIZZINESS (dizziness), ASTHENIA (weakness) and NAUSEA (nauseous). The patient was treated with IBUPROFEN at an unspecified dose and frequency. At the time of the report, SOMNOLENCE (could not get out of bed), DIZZINESS (dizziness), ASTHENIA (weakness) and NAUSEA (nauseous) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Most recent FOLLOW-UP information incorporated above includes: On 15-Feb-2021: No specific follow-up information recorded.
Covid vaccine was given to recipient that was diluted incorrectly.  Nurse who gave it diluted the vial in 0.8mL instead of 1.8mL. No known adverse reactions at this time.
No known issues, pt got a 3rd dose which is not recommended. Patient requested second dose at our pharmacy, had gotten a dose at another previously and had a vaccination card indicating first dose only had been administered. Upon accessing the state record though it became evident that a  had already administered his first dose 3/16 and the "first" dose we saw on 4/25 was actually his second. a third dose of vaccine is not in the recommendation
48 year female who received Td shot in right arm on 4/24/2007. Within 48 hrs notice redness, swelling, pain, and itching of injection site. Area of erythema 11 x 11 cm.  This injection of TD was given at hospital on 4/24/07.  We don't know the lot # or manufacturer.
30 yo female with PMHx severe anaphylactic food allergies (peanuts, beans, shellfish), who presented for her firstdose of Pfizer COVID vaccine today. She was otherwise in her USH, received her vaccine at 2:45 PM. About 15 minutes later, began having chest pressure and SOB. Chest pressure, substernal, 8/10, w/o radiation, nonpleuritic, nonpositional, not exertional. +SOB "like I'm trying to catch my breath". No wheezing, tachypnea, tongue/throat  itching/closing, runny nose, N/V, abd pain, diarrhea, hives. No LH, palp, diaphoresis.  Prev h/o food allergies with severe hives, SOB, troat closing.  Usually takes Benadryl with resolution. No h/o epipen use. Does not have her own epipen. Had lunch at 1 PM, does not think it she was exposed to any known allergens. On initial evauation: VS: T 98.6F,  BP 140s/90s, HR 120s, RR, SaO2 99% RA. Gen: WDWN, NAD. HEENT: NCAT, sclera anicteric and w/o injection, MMM OP clear. Neck: supple, good ROM. CV: tachy, reg rhythm, S1, S2. No m/r/g. Pulm: CTAB. No wheezes or crackles. No stridor. Abd: S, NT, ND. NABS. No rebound or guarding. Extr: no c/c/e. Skin: no rashes Neuro: A&Ox3. No focal deficits. Pt given Benadryl 50 mg po x1 with improvement in chest pressure in about 20 minutes, but no change in SOB. No further sxs. Repeat VS: 133/91, HR 93, R 20, SaO2 99%, RA 125/85, HR 80sR 20, SaO2 97% RA. As sxs persisted, EMS activated.
This is a spontaneous report from a non-contactable consumer. A 61-year-old female patient (not pregnant, age at vaccination reported as 61-years-old) received the second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number and expiry date unknown), via an unspecified route of administration (left arm), on 02Feb2021, at single dose, for covid-19 immunization. Medical history included sulfa allergies. The patient's concomitant medications were not reported. The patient previously received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number unknown), for covid-19 immunization. The patient felt flu like symptoms the day after the second vaccination dose on 03Feb2021. Symptoms have resolved on the second day after vaccination. The patient recovered from the adverse event on 04Feb2021. No treatment was received for the adverse event. The patient did not have COVID prior vaccination and have not been COVID tested post vaccination.  No follow-up attempts are possible; information about the lot/batch number cannot be obtained.
22MAR92 woke up w/large red blotches on belly & ribs afternoon spread to under arms, diaper area & thighs, evening spread to neck & behind ears & seemed to run together, t100.4 R;
Within 15-minutes of vaccination, EMS evaluated the patient for "focal seizure like activity". No other information was given and no EMS report was submitted for the incident. There have been no hospital visits identified for the patient's condition.
The morning after taking first injection I started my menstrual cycle which was 9 days early. I never start even a day early. I also had a heavy nose bleed on that day after my first vaccination.
COVID 19 treatment; COVID 19 treatment; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 55-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 26May2021 as dose 1, single (Lot number: EW0191), in left arm, on 16Jun2021 as dose 2, single (Lot number: EW0196), in left arm and on 28Feb2022 at 09:30 as dose 3 (booster), single (Lot number: 331300A) at the age of 54 years, in left arm for covid-19 immunisation. The patient's relevant medical history included: "Known allergies: Sulfa" (unspecified if ongoing), notes: Known allergies: Sulfa; Codeine; Bydurion; Ozempic; Emycin; "Diabetes" (unspecified if ongoing); "Asthma" (unspecified if ongoing); "Hiatal Hernia" (unspecified if ongoing); "Obesity" (unspecified if ongoing); "Migraines" (unspecified if ongoing), notes: Migraines; "Environmental allergies" (unspecified if ongoing), notes: Environmental allergies. Concomitant medication(s) included: BREO ELLIPTA, start date: 01Feb2021, stop date: Jul2022; JARDIANCE, start date: 01Feb2021, stop date: Jul2022; ESCITALOPRAM, start date: Feb2021, stop date: Jul2022; BUPROPION HCL XL, start date: Feb2021, stop date: Jul2022; DEXILANT, start date: Feb2021, stop date: Jul2022; CETIRIZINE, start date: Feb2021, stop date: Jul2022. Past drug history included: Codeine, reaction(s): "Known allergies: Codeine", notes: Known allergies: Sulfa; Codeine; Bydurion; Ozempic; Emycin; Bydureon, reaction(s): "Known allergies: Bydureon", notes: Known allergies: Sulfa; Codeine; Bydureon; Ozempic; Emycin; Ozempic, reaction(s): "Known allergies: Ozempic", notes: Known allergies: Sulfa; Codeine; Bydurion; Ozempic; Emycin; Emycin, reaction(s): "Known allergies: Emycin", notes: Known allergies: Sulfa; Codeine; Bydurion; Ozempic; Emycin. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset Jul2022, outcome "unknown" and all described as "COVID 19 treatment". Therapeutic measures were taken as a result of vaccination failure, covid-19.  Clinical course: It was reported that report was about COVID treatment. The patient had received other medication in 2 weeks. Anti viral details: Product: COVID 19 treatment, brand: Paxlovid. The patient was taking any other medications/products within 2 weeks of starting COVID-19 treatment. The patient had previously received a COVID-19 Vaccine. The device date was reported as 18Jul2022.
The night before my symptoms started. I first was feeling something similar to allergies. I had a sore throat in the morning and congestion. What really made me know I was tired and sleeping a lot. I went to a pharmacy and test with a at home test and it was positive. I called my doctor, and they just wanted me to stay at home and take over the counter medication. A couple times I had body ache, but it didn't last long cause of the medicine. I think I was sick for probably 5 or 6 days of sickness. The congestion was pretty much back to normal.
Papular rash, resembling chicken pox appeared on head and back on 3/5/15. 10-15 total lesions seen.
1/2 hour after "free" flu shot in 2003 muscle paralysis started in my thighs. I was driving at time! Paralysis and muscle problems spread throughout body over next 3 days. 1 month later still diff to get up. 13 yrs later still have residual problems.
Patients received the Moderna Covid 19 vaccine after temperature excursion; Patients received the Moderna Covid 19 vaccine after temperature excursion; This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (Patients received the Moderna Covid 19 vaccine after temperature excursion) and POOR QUALITY PRODUCT ADMINISTERED (Patients received the Moderna Covid 19 vaccine after temperature excursion) in a 71-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis.     No Medical History information was reported.    On 26-Apr-2022, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On 26-Apr-2022, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (Patients received the Moderna Covid 19 vaccine after temperature excursion). On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Patients received the Moderna Covid 19 vaccine after temperature excursion). At the time of the report, PRODUCT TEMPERATURE EXCURSION ISSUE (Patients received the Moderna Covid 19 vaccine after temperature excursion) and POOR QUALITY PRODUCT ADMINISTERED (Patients received the Moderna Covid 19 vaccine after temperature excursion) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication information was provided.  Reporter informed about temperature excursions with freezer in the facility, where she works. It had been happening for weeks since April 2022. The storage condition at the time of the excursion was reported as frozen storage. The affected batch lot numbers were reported as 065K21A and 045L21A. The temperatures excursion range was reported as maximum 30 Fahrenheit degrees and minimum minus18.9 Fahrenheit degrees. The vaccines suffered 2 temperature excursions since April, both of which lasted less than 1 minute. The vials were stored frozen. Visual inspection did not noted any vaccine state change. No treatment medication were provided.
Chills; Fever; Could not balance while walking; Feels weakness; legs are more weak; This spontaneous case was reported by a consumer and describes the occurrence of BALANCE DISORDER (Could not balance while walking), ASTHENIA (Feels weakness), MUSCULAR WEAKNESS (legs are more weak), CHILLS (Chills) and PYREXIA (Fever) in a 79-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 05-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 05-Apr-2021, the patient experienced BALANCE DISORDER (Could not balance while walking), ASTHENIA (Feels weakness) and MUSCULAR WEAKNESS (legs are more weak). On 06-Apr-2021, the patient experienced CHILLS (Chills) and PYREXIA (Fever). On 08-Apr-2021, CHILLS (Chills) and PYREXIA (Fever) had resolved. At the time of the report, BALANCE DISORDER (Could not balance while walking), ASTHENIA (Feels weakness) and MUSCULAR WEAKNESS (legs are more weak) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported.    Treatment medication included acetaminophen.   Most recent FOLLOW-UP information incorporated above includes: On 16-Jun-2021: Follow-up received, TCR added
Patient arrived to the emergency department with shortness of breath. Symptoms started Monday (11/22) with decreased appetite and then shortness of breath later in the day. Noted some pain in his left arm and tingling in his hand. He was diagnosed by the doctor with "Adverse reaction to COVID-19 vaccine." Patient was discharged home in stable condition.
Mild cellulitis (L) thigh extending medially noted 3d after vaccine given. No fever, NT but 8x4 cm are of redness treated with 5d course of Keflex
pt recvd vax & urticaria rash on forehead around eyes; lungs clear, heart NSR; pt pale; administered Epi; skin pale; 02 administration acute care clinic; given DPH;
Case number PHEH2011US02338 is an initial spontaneous report received from a physician on 22 Aug 2011. This report refers to a 13 years old female patient. She was given only the CYW-135 liquid component MENVEO (batch number: X10057) intramuscularly on 22 Aug 2011. No other adverse reaction was reported.
Information has been received from a physician concerning a female (age and gender unknown), who, on an unspecified date, was vaccinated with a dose of GARDASIL. Subsequently, the patient was diagnosed with guillain-barre syndrome. At the time of the report, the outcome of the patient was unknown. No product quality complaint was involved. Upon internal review, guillain-barre syndrome was considered to be an other important medical event. Additional information is not expected.
both he and his girlfriend experienced arm soreness after the Pfizer Covid vaccine dose.; This is a spontaneous report from a contactable consumer (patient) reported for himself. A male patient of an unspecified age received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Batch/Lot number: unknown, Expiration date: unknown), via an unspecified route of administration, administered at an unspecified anatomical location on an unspecified date as dose 1, single for COVID-19 immunization. The patient's medical history and concomitant medications were unknown. On an unspecified date the patient experienced both he and his girlfriend experienced arm soreness after the pfizer covid vaccine dose. The outcome of the events was unknown.  No Follow-up attempts are possible. Information about lot/batch cannot be obtained.